https://www.selleckchem.com/pr....oducts/pacritinib-sb
The mean age in Group 2 was lower by a decade (Group 1 vs. Group 2-59.45 vs 47.7 years). Haemodialysis was the most common kidney replacement therapy in both groups and conservative management of ESKD was the second commonest available treatment option within Group 2. The disease burden was expected to grow 20% in 50% of Group 1 countries and 78% of Group 2 countries along with the parallel growth in haemodialysis and peritoneal dialysis. 20% in 50% of Group 1 countries and 78% of Group 2 countries along with the parallel
Like
Comment
Share
